Randomised clinical trial: arbaclofen placarbil in gastro-oesophageal reflux disease–insights into study design for transient lower sphincter relaxation inhibitors.

For: All,

This study tested arbaclofen placarbil (a form of arbaclofen, a drug also being explored for neurodevelopmental conditions) as a treatment for acid reflux (GERD) in adults, finding it was not significantly better than placebo overall, though it showed more promise for people with moderate-to-severe symptoms — relevant to 16p11.2 families because GI issues like reflux are common in affected individuals and arbaclofen is of broader interest to this community.